UK regulators approve injectable form of nivolumab for solid tumours
The Medicines and Healthcare products Regulatory Agency (MHRA) in the [...]
Immunotherapy for the treatment of non-clear cell kidney cancer
There are several types of kidney cancer, the most common [...]
Europe has approved subcutaneous nivolumab for solid tumours
The Committee for Medicinal Products for Human Use (CHMP) of [...]
Health-related quality of life with belzutifan versus everolimus for advanced kidney cancer
People with kidney cancer have been shown to have changes (mutations) in [...]
Combinations of pembrolizumab and targeted therapies for advanced clear cell kidney cancer
The KEYMAKER-U03 study is looking at different combinations of immunotherapy [...]
FDA grants Priority Review status for TLX250-CDx for kidney cancer PET/CT scans
The Food and Drug Administration (FDA) in America has accepted [...]
New personalised cancer vaccine shows promise for advanced kidney cancer
A new personalised cancer vaccine has shown promising anti-tumour immunity [...]
Belzutifan approved in Europe for advanced kidney cancer and VHL disease
The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for [...]
Belzutifan plus cabozantinib combination shows promise in advanced kidney cancer
Updated results from the phase 2 LITESPARK-003 trial with belzutifan [...]
Promising new combination therapy for advanced kidney cancer
Combinations of tyrosine kinase inhibitors plus immunotherapy have improved treatment [...]
